All In Biotech

Drug Trial Radar · NCT03574597

Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

SELECT - Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity

Last checked: Nov 19, 2026Latest source record: Aug 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 17,604 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

17,604

Actual

Start

Oct 24, 2018

Primary completion

Jun 21, 2023

Study completion Jun 29, 2023

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Jul 2, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The researchers are doing the study to see if semaglutide may reduce the risk of having cardiovascular events in patients with overweight or obesity and with prior cardiovascular disease. The participant will either get semaglutide (active medicine) or placebo ("dummy" medicine). Which treatment the participants get is decided by chance. The participant's chance of getting semaglutide or placebo is the same. The participant will get the study medicine in a pen. The participants will need to use the pen to inject the study medicine in a skinfold once a week. The study will last for about 2.5 to 5 years. Participants will have up to 25 clinic visits with the study doctor.

Conditions

  • Overweight
  • Obesity

Interventions

  • SemaglutideDrug

    Semaglutide will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Subjects will start semaglutide treatment at 0.24 mg; dose will gradually be increased every 4 weeks up to 2.4 mg.

  • Placebo (semaglutide)Drug

    Placebo will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Participants will receive placebo at an equivalent dose to semaglutide.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal StrokeTime frame: From randomisation (week 0) up to 240 weeks

Locations

833 sites in 42 countries. Site status is shown where the registry gives one.

  • Central Alabama Research

    Birmingham, Alabama

  • Univ of Alabama Birmingham

    Birmingham, Alabama

  • Healthscan Clinical Trials,LLC.

    Montgomery, Alabama

  • Synexus Clinical Research US, Inc./Tatum

    Glendale, Arizona

  • Synexus Clinical Research

    Glendale, Arizona

  • Synexus Rsch /Cnt Phnx Med C

    Phoenix, Arizona

  • National Heart Institute Cal

    Beverly Hills, California

  • FDRC

    Costa Mesa, California

  • Valley Clinical Trials

    Covina, California

  • Scripps Whittier Diabetes Inst

    La Jolla, California

  • First Valley Medical Group

    Lancaster, California

  • Torrance Clin Res Inst, Inc.

    Lomita, California

  • Long Beach VA healthcare System

    Long Beach, California

  • Angel City Research, Inc.

    Los Angeles, California

  • VAGLAHS Clinical Research Center (CRC)

    Los Angeles, California

  • Riverside University Health System Medical Center

    Moreno Valley, California

  • Valley Clinical Trials, Inc.

    Northridge, California

  • Desert Oasis Hlthcr Med Group

    Palm Springs, California

  • Western University of Health Sciences

    Pomona, California

  • Quartz Hill Walk-in Medical Group, inc.

    Quartz Hill, California

  • TriWest Research Associates

    San Diego, California

  • San Diego Family Care

    San Diego, California

  • Mills-Peninsula Medical Center

    San Mateo, California

  • NorCal Endocrinology and Internal Medicine

    San Ramon, California

  • Encompass Clinical Research_Spring Valley

    Spring Valley, California

  • Lundquist Inst-Biomed Innovtn

    Torrance, California

  • Synexus Clinical Research US, Inc._Horsham

    Vista, California

  • University of Colorado Hospital

    Aurora, Colorado

  • Optumcare Colorado Springs, LLC

    Colorado Springs, Colorado

  • Optumcare Colorado Springs

    Colorado Springs, Colorado

  • New West Physicians,Inc.

    Golden, Colorado

  • Optumcare Colorado Springs, LLC_Monument

    Monument, Colorado

  • Bridgeport Hospital

    Bridgeport, Connecticut

  • Yale University School Of Medicine

    New Haven, Connecticut

  • Chase Medical Research LLC

    Waterbury, Connecticut

  • Excel Med Ctr Clinical Trials

    Boca Raton, Florida

  • Bradenton Research Center

    Bradenton, Florida

  • Clearwater Cardiovascular Consultants

    Clearwater, Florida

  • Nature Coast Clin Rsrch_Crystal River

    Crystal River, Florida

  • Florida Premier Cardiology

    Delray Beach, Florida

Showing 40 of 833 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.